ARGXargenxSigning up patients
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
AChR-Ab Seropositive Generalized Myasthenia Gravis · Myasthenia Gravis (MG) · MG - Myasthenia Gravis · gMG
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 40 (planned)
- Started
- Jul 10, 2026
- Main results expected
- Oct 2027
- Fully finished
- Apr 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of adverse events and serious adverse events in the DBTP
Measured over: Up to 12 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07673627 · record last updated 2026-11-04 · checked 2026-11-09 15:47 UTC